 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...197198199200201202203204205206207...235236» |
- Avastin (bevacizumab) / Roche
Enrollment open, Trial initiation date, Combination therapy: Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable Metastasis (clinicaltrials.gov) - Aug 22, 2016
P2, N=44, Enrolling by invitation, Sponsor: Gachon University Gil Medical Center
Not yet recruiting --> Enrolling by invitation | Initiation date: May 2015 --> Aug 2015
- Trial completion, Metastases: Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - Aug 19, 2016
P2, N=60, Completed, Sponsor: Pancreatic Cancer Research Team
Not yet recruiting --> Enrolling by invitation | Initiation date: May 2015 --> Aug 2015 Active, not recruiting --> Completed
- ||| monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Enrollment open, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) - Aug 19, 2016
P1, N=232, Recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2019 --> Sep 2019
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P3 trial: CheckMate 649: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (clinicaltrials.gov) - Aug 19, 2016
P3, N=750, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- New P1 trial, Metastases: A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Aug 18, 2016
P1, N=34, Not yet recruiting, Sponsor: University of Colorado, Denver
- Trial primary completion date, Surgery: A021501: Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer (clinicaltrials.gov) - Aug 18, 2016
P2, N=134, Not yet recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2019 --> Sep 2019 Trial primary completion date: Feb 2024 --> Mar 2020
- ||| imalumab (BAX069) / Takeda, Vectibix (panitumumab) / Amgen
Enrollment closed, Phase classification, Enrollment change: Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 17, 2016
P2a, N=112, Active, not recruiting, Sponsor: Baxalta US Inc.
Trial primary completion date: Feb 2024 --> Mar 2020 Recruiting --> Active, not recruiting | Phase classification: P2 --> P2a | N=90 --> 112
- ||| simmitecan / HaiHe Biopharma, Shanghai Inst. of Materia Medica
New P1 trial, Monotherapy, Metastases: Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 16, 2016
P1, N=158, Not yet recruiting, Sponsor: ShangHai HaiHe Pharmaceutical
- Farydak (panobinostat) / Secura Bio
Phase classification, Combination therapy: Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Aug 16, 2016
P1, N=36, Recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting | Phase classification: P2 --> P2a | N=90 --> 112 Phase classification: P1/2 --> P1
- || Avastin (bevacizumab) / Roche
Biomarker, Trial primary completion date, Metastases: Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 15, 2016
P2, N=52, Active, not recruiting, Sponsor: CR-CSSS Champlain-Charles-Le Moyne
Phase classification: P1/2 --> P1 Trial primary completion date: Jan 2016 --> Oct 2016
- Avastin (bevacizumab) / Roche
New P1/2 trial: IPOXA: Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis (clinicaltrials.gov) - Aug 15, 2016
P1/2, N=47, Not yet recruiting, Sponsor: Hospices Civils de Lyon
- Avastin (bevacizumab) / Roche
Trial initiation date, Trial primary completion date: Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer (clinicaltrials.gov) - Aug 11, 2016
P1, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Jan 2016 --> Oct 2016 Initiation date: Nov 2008 --> Mar 2009 | Trial primary completion date: Sep 2016 --> Sep 2017
- || Hepacid (pegargiminase) / Polaris Pharma
Enrollment change, Trial primary completion date, Metastases: Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 11, 2016
P1, N=148, Recruiting, Sponsor: Polaris Group
Initiation date: Nov 2008 --> Mar 2009 | Trial primary completion date: Sep 2016 --> Sep 2017 N=22 --> 148 | Trial primary completion date: Dec 2016 --> Aug 2017
- leucovorin calcium / Generic mfg.
Enrollment change, Combination therapy: Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas (clinicaltrials.gov) - Aug 11, 2016
P1, N=18, Recruiting, Sponsor: City of Hope Medical Center
N=22 --> 148 | Trial primary completion date: Dec 2016 --> Aug 2017 N=24 --> 18
- Erbitux (cetuximab) / Eli Lilly
Biomarker, Enrollment closed, Trial primary completion date, Metastases: POSIBA: Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab (clinicaltrials.gov) - Aug 11, 2016
P2, N=170, Active, not recruiting, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
N=24 --> 18 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Dec 2016
- Enrollment open: Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study (clinicaltrials.gov) - Aug 11, 2016
P=N/A, N=28, Recruiting, Sponsor: University of Chicago
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Dec 2016 Not yet recruiting --> Recruiting
- | New P2 trial, Metastases: Multicenter RCT of the Clinical Effectiveness of Oncothermia With Chemotherapy in Metastatic Pancreatic Cancer Patients (clinicaltrials.gov) - Aug 10, 2016
P2, N=100, Not yet recruiting, Sponsor: Seoul National University Hospital
- alisertib (MLN8237) / Puma
Trial primary completion date, Combination therapy: Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors (clinicaltrials.gov) - Aug 9, 2016
P1, N=30, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2016 --> Apr 2017
- || veliparib (ABT-888) / AbbVie
Trial primary completion date, Metastases: Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 8, 2016
P2, N=120, Active, not recruiting, Sponsor: AbbVie
Trial primary completion date: Apr 2016 --> Apr 2017 Trial primary completion date: Oct 2016 --> May 2017
- veliparib (ABT-888) / AbbVie
Trial primary completion date, Combination therapy: A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors (clinicaltrials.gov) - Aug 8, 2016
P1, N=48, Active, not recruiting, Sponsor: AbbVie
Trial primary completion date: Oct 2016 --> May 2017 Trial primary completion date: Mar 2016 --> Nov 2016
- || dilpacimab (ABT-165) / AbbVie
Trial primary completion date, Metastases: A Study of ABT-165 in Subjects With Solid Tumors (clinicaltrials.gov) - Aug 8, 2016
P1, N=90, Recruiting, Sponsor: AbbVie
Trial primary completion date: Mar 2016 --> Nov 2016 Trial primary completion date: Aug 2016 --> Apr 2017
- oxaliplatin / Generic mfg., cisplatin / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date, Metastases: ABC06: Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers (clinicaltrials.gov) - Aug 8, 2016
P3, N=162, Recruiting, Sponsor: The Christie NHS Foundation Trust
Trial primary completion date: Aug 2016 --> Apr 2017 Trial primary completion date: Jun 2017 --> Jan 2018
- Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: Study of Vitamin D in Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 8, 2016
P2, N=120, Recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Jun 2017 --> Jan 2018 Trial primary completion date: Jul 2016 --> Nov 2016
- Avastin (bevacizumab) / Roche, apitolisib (GDC-0980) / Roche
Trial primary completion date, Combination therapy, Metastases: GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 8, 2016
P1, N=43, Completed, Sponsor: Genentech, Inc.
Trial primary completion date: Jul 2016 --> Nov 2016 Trial primary completion date: Dec 2014 --> Jun 2015
- | New P2 trial, Metastases: Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN) (clinicaltrials.gov) - Aug 5, 2016
P2, N=162, Not yet recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- New P2 trial, Metastases: Metronomic Chemotherapy in Advanced Gastric Cancer (clinicaltrials.gov) - Aug 4, 2016
P2, N=40, Recruiting, Sponsor: Huashan Hospital
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Biomarker, Trial completion, Surgery: Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery (clinicaltrials.gov) - Aug 3, 2016
P3, N=1535, Completed, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Trial primary completion date: Dec 2014 --> Jun 2015 Active, not recruiting --> Completed
- | MM-151 / Merrimack
Enrollment open, Metastases: Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 3, 2016
P1/2, N=28, Recruiting, Sponsor: Merrimack Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., everolimus / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Metastases: Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer (clinicaltrials.gov) - Jul 29, 2016
P1/2, N=6, Completed, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=44 --> 6 | Trial primary completion date: Apr 2017 --> Jul 2016
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
New trial, Metastases: CULTURE3D: Predictive Response to Chemotherapy (FOLFOX or FOLFIRI) by ex Vivo Culture 3D Technique in Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 29, 2016
P=N/A, N=22, Completed, Sponsor: Institut Curie
- varlitinib (ASLAN001) / ASLAN Pharma
Trial primary completion date, Combination therapy: Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine (clinicaltrials.gov) - Jul 28, 2016
P1, N=24, Recruiting, Sponsor: Aslan Pharmaceuticals
Active, not recruiting --> Completed | N=44 --> 6 | Trial primary completion date: Apr 2017 --> Jul 2016 Trial primary completion date: Jun 2016 --> Dec 2017
- New P2 trial, Metastases: SYLT: POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC (clinicaltrials.gov) - Jul 27, 2016
P2, N=30, Enrolling by invitation, Sponsor: Fujian Cancer Hospital
- Trial primary completion date, Surgery: Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") (clinicaltrials.gov) - Jul 25, 2016
P2, N=120, Recruiting, Sponsor: Medical College of Wisconsin
Trial primary completion date: Jun 2016 --> Dec 2017 Trial primary completion date: Dec 2016 --> Jun 2017
- Trial primary completion date: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors (clinicaltrials.gov) - Jul 25, 2016
P3, N=190, Suspended, Sponsor: Tufts Medical Center
Trial primary completion date: Dec 2016 --> Jun 2017 Trial primary completion date: Apr 2016 --> Oct 2013
- Otrexup (methotrexate) / Halozyme, Rituxan (rituximab) / Roche
Trial primary completion date: Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma (clinicaltrials.gov) - Jul 23, 2016
P2, N=28, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2016 --> Oct 2013 Trial primary completion date: Jul 2016 --> Jul 2018
- || leucovorin calcium / Generic mfg.
New P3 trial: Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder (clinicaltrials.gov) - Jul 23, 2016
P3, N=160, Not yet recruiting, Sponsor: Emory University
- Trial primary completion date, Combination therapy, IO biomarker: Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma (clinicaltrials.gov) - Jul 22, 2016
P2, N=26, Suspended, Sponsor: University of Miami
Trial primary completion date: Jul 2016 --> Jul 2018 Trial primary completion date: Apr 2016 --> Apr 2019
- | New P2 trial, Surgery: A021501: Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer (clinicaltrials.gov) - Jul 20, 2016
P2, N=124, Not yet recruiting, Sponsor: Alliance for Clinical Trials in Oncology
- Avastin (bevacizumab) / Roche, Stivarga (regorafenib) / Bayer
Trial termination, Metastases: PREVIUM: Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab (clinicaltrials.gov) - Jul 19, 2016
P2, N=15, Terminated, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Trial primary completion date: Apr 2016 --> Apr 2019 Active, not recruiting --> Terminated; The trial was prematurely closed due to lack of accrual
- Avastin (bevacizumab) / Roche
Metastases: BeTRI: Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 19, 2016
P2, N=45, Recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Active, not recruiting --> Terminated; The trial was prematurely closed due to lack of accrual Trial primary completion date: Mar 2016 --> Sep 2018
- Trial primary completion date: PACHA-01: Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases (clinicaltrials.gov) - Jul 19, 2016
P2/3, N=220, Recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Trial primary completion date: Mar 2016 --> Sep 2018 Trial primary completion date: May 2025 --> May 2026
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: Rectal Cancer, Adjuvant Chemotherapy, FOLFOX(5-fluorouracil/Leucovorin/Oxaliplatin), Total Mesorectal Excision (clinicaltrials.gov) - Jul 19, 2016
P3, N=580, Recruiting, Sponsor: Yonsei University
Trial primary completion date: May 2025 --> May 2026 Trial primary completion date: May 2016 --> May 2018
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Metastases: IriGen: Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 19, 2016
P2, N=47, Recruiting, Sponsor: Centre Jean Perrin
Trial primary completion date: May 2016 --> May 2018 Trial primary completion date: Jun 2015 --> Jul 2016
- Trial primary completion date, Metastases: FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Jul 19, 2016
P2, N=45, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Jun 2015 --> Jul 2016 Trial primary completion date: Jan 2016 --> Oct 2014
- Trial primary completion date: FOLFIRINOX + RT for Pancreatic Cancer (clinicaltrials.gov) - Jul 19, 2016
P2, N=50, Recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Jan 2016 --> Oct 2014 Trial primary completion date: May 2016 --> Sep 2016
- | Avastin (bevacizumab) / Roche, parsatuzumab (RG7414) / Roche
Trial termination, Combination therapy, Metastases: A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 19, 2016
P2, N=128, Terminated, Sponsor: Genentech, Inc.
Trial primary completion date: May 2016 --> Sep 2016 Completed --> Terminated
- ||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment closed, Enrollment change, Metastases: Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer (clinicaltrials.gov) - Jul 18, 2016
P2, N=56, Active, not recruiting, Sponsor: Richard Goldberg
Completed --> Terminated Recruiting --> Active, not recruiting | N=70 --> 56
- | Rituxan (rituximab) / Roche
Trial completion: Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma (clinicaltrials.gov) - Jul 17, 2016
P2, N=79, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting | N=70 --> 56 Active, not recruiting --> Completed
- New P1 trial, Combination therapy: Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI (clinicaltrials.gov) - Jul 14, 2016
P1, N=16, Recruiting, Sponsor: University of Massachusetts, Worcester
- | otilimab (GSK3196165) / GSK
Enrollment open, Combination therapy: Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - Jul 13, 2016
P2a, N=40, Recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Not yet recruiting --> Recruiting